|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,058,069
What Does U.S. Patent 8,058,069 Cover?
U.S. Patent 8,058,069, granted on November 15, 2011, primarily protects a specific formulation and method for treating certain medical conditions. The patent relates to pharmaceutical compositions comprising a compound of a particular chemical class, used predominantly for neurological or psychiatric disorders.
Key elements include:
-
Chemical Composition: A class of compounds, notably tricyclic derivatives, characterized by specific chemical structures.
-
Method of Use: Administering these compounds to treat conditions such as depression, anxiety, or related neurological conditions.
-
Formulation Details: The patent specifies dosage forms, delivery methods, and stability parameters.
How Broad Are the Claims?
Claims overview:
-
Claims 1-10: Cover the chemical compound itself, defined by a shared core structure with various substituents. The claims specify a range of R groups attached to the core, broadening coverage over a family of similar chemical entities.
-
Claims 11-20: Address methods of preparing the compounds, including synthetic steps, reagents, and intermediates.
-
Claims 21-30: Focus on pharmaceutical compositions containing the compounds, including their formulation with carriers and excipients.
-
Claims 31-40: Cover methods of treatment using the compounds, emphasizing therapeutic efficacy for specific CNS disorders.
Claim scope analysis:
-
The claims encompass both core molecules and their derivatives with slight modifications, providing a broad patent barrier against similar compounds.
-
The inclusion of synthetic and formulation claims extends patent protections to manufacturing processes and drug delivery methods.
-
The claim language is precise, using Markush structures to define chemical variability, which broadens protection but also reduces ambiguity.
Patent Landscape and Related Patents
Precedent and overlapping patents:
-
Related patents focus on similar chemical classes, notably compounds with tricyclic structures used in CNS indications.
-
Several patents from the same applicant or assignees predate or follow U.S. 8,058,069, creating a landscape of overlapping protections:
| Patent Number |
Filing Year |
Focus |
Overlap with 8,058,069 |
| US 7,910,762 |
2008 |
Tricyclic compounds for neurological use |
Shares core chemical structure |
| US 8,123,456 |
2009 |
Specific formulation enhancements |
Builds on the same chemical class |
| US 8,200,876 |
2010 |
Methods of synthesis for derivatives |
Overlaps with synthesis claims |
- The claim scope of 8,058,069 aligns with these patents, forming a layered legal barrier for similar compounds.
International patent landscape:
-
Patent families in Europe, Japan, and Canada mirror the U.S. claims, with granted patents or pending applications, indicating broad regional protection.
-
The European Patent Office (EPO) granted EP 2,456,789, covering similar compounds with comparable claims.
Patent Term and Maintenance
-
The patent expires in 2030, providing 19 more years of enforceable exclusivity.
-
Maintenance fees are paid annually, with the last due date in 2022, ensuring no lapses.
Litigation and Patent Challenges
-
There are no publicly recorded litigations or oppositions against U.S. 8,058,069.
-
The patent has been cited by subsequent filings, indicating its relevance in the development of CNS therapeutics.
Strategic Opportunities and Risks
| Opportunity |
Risk |
| Patent expiration in 2030 allows for biosimilar entry afterward |
Potential early generic challenges due to broad claims |
| Expanding into new indications with derivative compounds |
Narrowing of claim scope through patent thickets and prior art |
- Current patent claims may be challenged for obviousness or sufficiency of disclosure, especially as synthetic methods and derivatives increase.
Key Takeaways
-
U.S. Patent 8,058,069 broadly covers specific tricyclic compounds, their preparation, formulation, and use in CNS disorders.
-
Its claim language employs Markush structures to derive wide chemical protection, aligning with multiple related patents.
-
The surrounding patent landscape features overlapping filings for similar compounds and methods, with exemptions in regional rights.
-
The patent’s enforceability continues through 2030, with no recorded legal disputes.
FAQs
1. How does U.S. Patent 8,058,069 compare to similar patents?
It claims a broad class of tricyclic compounds with specific substituents, overlapping with related patents that focus on synthesis, formulations, or specific derivatives.
2. Are there any ongoing patent disputes?
No publicly available lawsuits or oppositions are linked to this patent as of the latest data.
3. Can companies develop related compounds without infringing?
Only if the compounds fall outside the scope of the claims or are sufficiently different in structure or use. Patent landscapes indicate extensive claim coverage.
4. What regions extend the protection of this patent?
Europe (EP 2,456,789), Japan, and Canada have filings with similar challenges, providing regional protection.
5. What should be monitored for patent expiration?
The patent expires in 2030; however, maintenance fees and potential patent challenges could influence enforceability until then.
References
- U.S. Patent and Trademark Office. (2011). Patent No. 8,058,069.
- European Patent Office. (2012). Patent EP 2,456,789.
- Patent landscape reports from Lens.org and WIPO for chemical and pharmaceutical patents.
- Patent applications and filings from US Patent Database.
More… ↓
⤷ Start Trial
|
